Foghorn Therapeutics

Foghorn Therapeutics, founded in 2015 and headquartered in Cambridge, Massachusetts, is pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression. The company focuses on the chromatin regulatory system, which orchestrates gene expression by unpacking the 3D structure of DNA. Foghorn’s precision therapeutic candidates target disease dependencies within this system, altering how genes turn on and off. Leveraging its proprietary Gene Traffic Control® platform, Foghorn identifies and validates new drug targets within the chromatin regulatory system, developing therapies for cancer and other diseases. The company has a broad pipeline of product candidates, including enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Its lead product candidate, FHD-286, is an enzymatic inhibitor of BRG1 and BRM, currently in clinical development for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Foghorn collaborates with Loxo Oncology at Lilly on the co-development and co-commercialization of the selective BRM oncology program and an additional undisclosed oncology target. The company went public on the NASDAQ Global Market under the ticker symbol FHTX in October 2020. Foghorn’s therapies aim to transform the lives of people with a wide spectrum of diseases, including many types of cancer, and the company is actively conducting clinical trials to evaluate the safety and effectiveness of its new therapies. The Gene Traffic Control® platform allows Foghorn to study and target the chromatin regulatory system at scale, in context, and in an integrated way, making it the only company with this capability. The platform is broadly applicable to other chromatin remodeling complexes, transcription factors, and diseases, and Foghorn has identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders, and transcription factor disruptors.